• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    Pfizer, BioNTech Adapt COVID Vax Against Omicron

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    IDT Biologika

    Vector Partners Limited

    Qosina

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    IDT Biologika

    Vector Partners Limited

    Qosina

    Aphena Pharma Solutions

    Kyongbo Pharmaceutical
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Viral Contaminant Testing in Biopharma Manufacturing

    There is no single test to detect all potential viral contaminants in biopharmaceutical manufacturing.

    Viral Contaminant Testing in Biopharma Manufacturing
    Viral Contaminant Testing in Biopharma Manufacturing
    Viral Contaminant Testing in Biopharma Manufacturing
    Viral Contaminant Testing in Biopharma Manufacturing
    Related CONTENT
    • Reed-Lane
    • Janssen Receives FDA Approval for INVOKANA
    • Alcami Collaborates with Medicines Development for Global Health
    • Reporting CPPs to FDA
    • Symbiosis Secures FDA Approval
    Richard Adair, Virology Manager, SGS Life Sciences, Glasgow, UK11.13.18
    Proving the absence of something is far more complicated that detecting its presence, so tests to rule out the presence of viral contaminants in biopharmaceutical manufacturing will never yield a definitive result. Additionally, since it is obviously not possible to test the entire product, there is a statistical chance that low-level contaminants may be missed during analysis. These are just two of the challenges that the industry faces as biologic-based medicines continue to grow in importance.

    In theory, one single infectious virus particle may be sufficient to initiate an infection that could have potentially dangerous, or even fatal, consequences in humans, and this is especially true in vulnerable patients, whose immune system could already be compromised. Even viruses that are not known to cause significant disease in humans could, potentially, do so if introduced by a non-natural route of infection, such as by injection rather than respiratory or oral spread. Contamination with retroviruses is a particular concern, because they integrate into the host cell genome as part of their lifecycle, and can result in life-long infection or cellular change.

    Since viruses replicate within living organisms, any system used to generate biological or biopharmaceutical products could be at risk of viral contamination. There have been a number of well-documented instances of contaminated vaccines transmitting viruses to humans, such as batches of poliovirus and adenovirus vaccines that were found to be contaminated with Simian vacuolating virus 40 (SV40) from rhesus monkey kidney cells in the late 1950s and early 1960s; and some early batches of yellow fever vaccine produced in hens’ eggs were found to be contaminated with avian leucosis virus.

    More recently, there has been transmission of hepatitis A, B and C viruses, HIV and B19 via human blood products. However, viral contamination does not necessarily result in infection, and there are also examples of viruses being detected in cell culture-derived products without transmission to humans or animals (see Table 1).

    Virus contamination could arise from the presence of virus in the original cell line or biological system used, or from the inadvertent introduction of virus into cell cultures during a manufacturing process. Potential contamination sources could include raw materials of animal origin, the human operator, or materials contaminated by contact with animals or animal-derived material. For example, contamination of Chinese hamster ovary (CHO) cell banks with murine minute virus (MMV)—a virus primarily transmitted in the urine of rats and mice—could, potentially, have resulted from this latter route. Although there is significant pressure in the industry to move to serum-free conditions for cells to reduce the risk of contaminants, if cell banks and cell lines have been exposed historically to bovine serum or porcine trypsin, then they could potentially be affected by a range of bovine and/or porcine viral contaminants.

    Three principal and complementary approaches are generally applied for controlling viral contaminants in biologics: first, the selection and control of starting materials; second, the testing of source materials and the products; and finally, viral clearance.

    Regulatory authorities require testing to be carried out at every stage of the product’s manufacturing process. These include cell substrate banks, viral seed banks, raw materials of animal origin, bulk harvests, and the batches of the final manufactured clinical product. The samples must be tested to recognized international guidelines, such as the International Conference on Harmonization (ICH) guidelines, FDA Vaccine 2010 guidelines, and/or European Pharmacopeia guidelines, as appropriate.

    As there is no single method that will be able to detect all potential viral contaminants, a holistic approach is required involving a combination of methodologies with both general and specific assays. These will typically include: adventitious agent tests, usually non-specific tests capable of detecting a broad range of viruses; species-specific assays, designed to detect the presence of identified potential contaminants (e.g. specific bovine or porcine viruses in serum or trypsin, respectively, or murine viruses in mouse cells); and tests for retroviruses.

    In vitro and in vivo assays can be used to look for evidence of infectivity in a living system, while electron microscopy (EM), polymerase chain reaction (PCR)-based methods, and immunoassays look for viral markers, including the presence of virus particles, the virus genome, viral proteins or enzyme activity (see Figure 1).

    Infectivity assays are routinely used to screen for the presence of infectious virus contaminants, whether these are non-specific for the detection of adventitious virus contaminants, or specific for the detection of specific bovine, porcine, murine or hamster viruses. If a virus is to be detectable, it must be able to infect, and grow within, the indicator cell line(s) under the conditions used, and induce cytopathology or an alternative detectable effect. By using a range of cell lines capable of supporting the growth of different viruses, and appropriate end-points, in vitro assays may allow a broad range of adventitious virus contaminants to be detected.

    Electron microscopy is used widely as a generalized non-specific screening method. It allows direct visualization inside cells or samples, and can enable the detection of a broad range of viruses, as well as other micro-organisms including bacteria, fungi and mycoplasma. It can also be a useful diagnostic and investigative tool in cell cultures if the presence of virus is suspected.
    Drawbacks to using EM are that it is a labor-intensive method and has low sensitivity, so a virus present in a very small proportion of a cell bank (e.g. 1 in 1000 cells) may not be detected in a standard assay where 200-300 cell profiles may be examined.

    Quantitative PCR (qPCR) and nucleic acid tests (NAT) are also widely used in the industry. Virus qPCR assays, such as TaqMan, are used to look for species-specific contaminant by nucleic acid amplification of the viral genome. Testing companies have hundreds of validated PCR reactions for a wide range of different potential viral contaminants of cell banks and cell lines, and these are selected based on a risk assessment of what the material is, and what it is ultimately going to be used for.

    PCR is highly prone to contamination, so rigorous testing controls must be put in place to segregate the PCR reagents and test materials in different cleanrooms, and to ensure that the workflow moves only in one direction to avoid cross-contamination. Other key controls are that nucleic acid recovery in each test item extraction is qualified by use of an internal spike control, and pathogen nucleic acid is also spiked into a test sample to ensure there is no interference from the presence of the test material.

    PCR can detect both infectious and non-infectious viruses, which is important because some contaminant viruses will not grow in culture systems. The method could, therefore, give an indication of a possible contaminant that may not be detected by an infectivity assay.

    However, a positive PCR result only indicates the presence of virus DNA or RNA, rather than reflecting whether the virus is infectious. Bovine polyoma virus, for example, is a well-known contaminant of serum, but a positive PCR result from serum cannot determine whether there is replicating virus present, or merely DNA fragments. Therefore, positive results from PCR assays may require further investigation and confirmatory tests to determine if infectious virus is present, such as infectivity assays.

    The specificity of PCR is both an advantage and a drawback, because the technique cannot find contaminants that are not being looked for. Furthermore, because PCR is specific, the target has to be highly conserved and the PCR reaction highly sensitive (<100-1000 copies per 200,000 non-infected cells for cell banks or <2000 copies per ml for vaccine seeds). For this reason, there is now a lot of interest in the industry in next generation sequencing (NGS), also known as massive parallel sequencing, deep sequencing or metagenomics. It is, essentially, a tool to screen a population of sequences in the sample and can be used to detect unknown viruses, integrated retrovirus provirus, transcripts and endogenous sequences.

    As stated above, retroviruses are of particular concern, and because they do not always exhibit a cytopathic effect, they cannot be detected by conventional culture methods. However, they express an enzyme called reverse transcriptase (RT), which is largely found in retroviruses, so RT activity is an indication of potential retrovirus contamination (see Figure 2).

    Retroviral RT enzyme activity can be detected by the use of PCR-based RT (PBRT) or product-enhanced RT (PERT), but although PERT assays are highly sensitive, they can sometimes give false positives from high background cellular DNA polymerase activity. Therefore, unexpected PERT positive results need to be confirmed by retroviral infectivity testing, using a relevant detector cell line(s).

    The third stage of controlling viral contaminants in biopharmaceuticals is viral clearance—downstream processing of the product by putting it through a filtration process or subjecting it to high pH conditions or high temperatures to further reduce the risk of the presence of infectious virus contaminants. But while this is suitable for some biologics, it cannot be used in the manufacture of live viral vaccines or viral vectors because it would render the product ineffective. For this reason, the focus on the testing of the materials and the products is crucial in viral vectors and vaccines manufacture.

    All of these methodologies have limitations, in terms of both their respective limits of detection and levels of specificity. The absence of an infectious agent can never be entirely proven—it is only possible to achieve negative test results. The only realistic approach to take is to assess the risk based on the materials being used, the production methods and the eventual clinical application, and then test accordingly. 
    Related Searches
    • biologics
    • Biopharma
    • in vivo
    • it
    Suggested For You
    Reed-Lane Reed-Lane
    Janssen Receives FDA Approval for INVOKANA Janssen Receives FDA Approval for INVOKANA
    Alcami Collaborates with Medicines Development for Global Health Alcami Collaborates with Medicines Development for Global Health
    Reporting CPPs to FDA Reporting CPPs to FDA
     Symbiosis Secures FDA Approval Symbiosis Secures FDA Approval
    Oxford Genetics & ERS Genomics Extend Agreement Oxford Genetics & ERS Genomics Extend Agreement
    BIA Separations Opens New Upstream Processing Facility BIA Separations Opens New Upstream Processing Facility
    Biosimilar  Market Trends Biosimilar Market Trends
    Haste Makes Waste Haste Makes Waste
    CDMOs and Drug Shortages CDMOs and Drug Shortages
    Key Biologics, BCA Partner for Cell Therapy Key Biologics, BCA Partner for Cell Therapy
    Pall, Celltheon Form Strategic Biotherapeutics Pact   Pall, Celltheon Form Strategic Biotherapeutics Pact
    FDA Approves Grifols FDA Approves Grifols' Facility for Production of Recombinant Proteins
    Rockwell Medical Announces FDA Approval Rockwell Medical Announces FDA Approval
    18	ALLERGAN 18 ALLERGAN

    Related Content

    • Serialization | Vials
      Reed-Lane

      Reed-Lane

      Reed-Lane is a privately owned contract packager located in northern New Jersey that has been serving the pharmaceutical market for over 60 years.
      Joe Luke, VP Sales & Marketing 10.25.19

    • Bio News | Clinical Trials | Industry News | R&D | Trials & Filings
      Janssen Receives FDA Approval for INVOKANA

      Janssen Receives FDA Approval for INVOKANA

      To reduce risk of major adverse cardiovascular events, in adults with type 2 diabetes (T2D) who have established CV disease
      10.30.18

    • Breaking News | Collaborations & Alliances | Industry News
      Alcami Collaborates with Medicines Development for Global Health

      Alcami Collaborates with Medicines Development for Global Health

      Helps the not-for-profit secure FDA approval of moxidectin for river blindness
      10.26.18


    • Regulatory Affairs
      Reporting CPPs to FDA

      Reporting CPPs to FDA

      Importance of identifying critical process parameters in original submissions to FDA.
      Aloka Srinivasan, Ph.D. Lachman, Consultant Services 10.10.18

    • Bio News | Facilities | Fill/Finish | Industry News | Trials & Filings
       Symbiosis Secures FDA Approval

      Symbiosis Secures FDA Approval

      For its viral vector manufacturing fill/finish process at its biologics manufacturing facility located in Scotland, UK
      09.24.18

      Loading, Please Wait..
      Trending
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • 17th Annual Contracting & Outsourcing Conference Photos
      • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
      • LabVantage Solutions Adds Mixed Reality Technology to Its Advanced LIMS Platform
      • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
      Breaking News
      • Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • CoreRx Expands Capabilities
      • Qosina Strengthens Aseptic Capabilities
      • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Japanese Mushroom Extract Appears Helpful in HPV Infections
      Fi & Hi Europe Returns with Over 20,000 Global Attendees Expected
      United Plant Savers Launches First Film Festival
      Coatings World

      Latest Breaking News From Coatings World

      H.M. Royal Becomes Exclusive OCSiAl Distributor
      American Colors to Expand Sandusky, Ohio Facility
      Vaughn O’Dea Named Director of Epoxytec
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Accelmed Partners II, Lauxera Capital Partners Invest in Veranex
      Agnes Lee Named SVP of Investor Relations, Strategic Planning at Inogen
      Dr. Brandee Pappalardo Joins Fresenius Kabi as Chief Medical Officer
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate
      Pfizer, BioNTech Adapt COVID Vax Against Omicron
      CoreRx Expands Capabilities
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Top 5 Beauty Tech Trends at Perfect Corp.'s Global Forum
      John Frieda Supports the LGBTQIA+ Community
      Athena Club Launches in Canada
      Happi

      Latest Breaking News From Happi

      Color Street Celebrates Foster, Adoption Awareness with Limited-Edition Print
      CIR Panel Conducts 161st Meeting Regarding Safety Assessments for Cosmetic Ingredients
      DIY Nail Care Is Outperforming the Professional Segment: Kline
      Ink World

      Latest Breaking News From Ink World

      Dr. Tammo Boinowitz to Join Management Board of ALTANA AG
      Flint Offset Packaging Solutions Announces Price Increases for Sheetfed Inks
      Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Harveer Sahni recognized with Global Achievement Award
      Color-Logic partners with Taktiful 
      ALTANA announces Management Board change
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Fibertex Personal Care Awarded EcoVadis Awards for Sustainability
      Yanpai Orders Batt Forming Equipment for Needlepunch Line
      Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Researchers Discover Novel Patching Material for Bone Defects
      Boston Centerless Opens Second Manufacturing Plant in Indiana
      Researchers Develop Patient-Specific 3D-Printed Smart Metamaterial Implants
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Identiv-Powered CVS Spoken Rx Wins NFC Forum 2022 Innovation Award
      LG Display Announces Winners of This Year’s OLEDs GO! Competition
      Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login